Nicotinamide Mononucleotide (NMN) is a precursor to nicotinamide adenine dinucleotide (NAD+), a molecule vital to cellular metabolism and energy production. Recent preclinical studies (mainly in animal models) have investigated NMN's effects on aging-related conditions such as osteoporosis. The rationale stems from findings that NAD+ levels decline with age, and this decline is implicated in impaired bone remodeling, decreased osteoblast function, and increased osteoclast activity—all relevant to osteoporosis pathogenesis.

Several rodent studies have demonstrated that NMN supplementation can increase NAD+ levels in bone tissue, enhance osteoblast activity, suppress osteoclastogenesis, and improve bone mineral density in models of age-related or ovariectomy-induced osteoporosis. For example, a 2022 study ("Nicotinamide mononucleotide supplementation improves bone regeneration and prevents bone loss in aging mice," Aging Cell) showed that NMN administration mitigated bone loss and improved bone microarchitecture in aging mice.

However, there are no published human clinical trials directly investigating NMN supplementation for osteoporosis prevention or treatment. The current evidence base is therefore limited to animal studies and mechanistic rationale. While these findings are promising and provide a scientific basis for further investigation, the evidence is not yet strong enough to recommend NMN as a treatment for osteoporosis in humans. More robust clinical research is required to confirm efficacy and safety in this context.